Narrator: This is Science Today. Dogs with lymphoma, who have otherwise not responded well to the standard treatment, have been involved in clinical trials at the University of California, Davis' School of Veterinary Medicine. Dr. Michael Kent has been treating dogs with a less-toxic, drug-delivery type of therapy developed by a researcher at the UC Davis Cancer Center. While it's too soon to test in humans with lymphoma, Kent says it's been promising in his canine patients.
Kent: I think that we're going to find that people also benefit greatly by the work that's being done to care for our pets who have cancer. I think this is going to be an area that we see the greatest advancements happen. It's a way to quickly, almost in a sense, screen new drugs and come up with the most promising ones that can then move forward to people.
Narrator: Kent says participating in translational research — the concept of teaming basic science researchers with clinicians — has been very exciting.
Kent: We can work so much better than staying isolated in your lab or just working with your patients. If everyone learns to work together, we can make big advancements probably a lot quicker than we could have otherwise.
Narrator: For Science Today, I'm Larissa Branin.